ANALISA IN SILICO KUNYIT (CURCUMA LONGA) SEBAGAI INHIBITOR MURINE DOUBLE MINUTE 2 PROTEIN UNTUK TERAPI GLIOBLASTOMA MULTIFORME
DOI:
https://doi.org/10.30649/obj.v3i2.61Keywords:
Glioblastoma multiforme, Curcuma longa, MDM 2, Autodock 4.2Abstract
Brain tumor consists of tumor which grows primarily from cells in the brain (primary
brain tumor) or systemic tumor which metastasized into the brain (secondary brain tumor).
From all types of primary brain tumor, Glioblastoma Multiforme is the most common and
the most malignant tumor. In 85% of Glioblastoma Multiforme cases are found a
molecular alteration of the tumor suppresor gene p53 pathway, which promotes current
studies to focus on this pathway. One of the pathway that can be used as therapeutic
model is through inhibiting the murine double minute 2 protein (MDM2), which in itself is
a p53 inhibitor. Turmeric (curcuma longa) is one of the traditional plants which is
commonly used as herbs and its extracts has been studied to have an anti-cancer
properties.
This study is an in silico study which evaluate the potential efficacy of turmeric
extract as a murine double minute 2 protein inhibitor using AutoDock 4.2 based on the
Lamarckian genetic algorithm principle. Docking result shows binding energy ranging
from -4.81 kcal/mol to -2.34 kcal/mol, with curcumenol having the lowest binding energy
and curcumin having the highest binding energy. This study may be used as a base in
further study (consists of in vivo and in vitro) of turmeric extract and its effect as the
therapeutic regiments for Glioblastoma Multiforme.
References
Adejoro, I., Waheed, S. and Adeboye, O. (2016). Molecular Docking Studies of
Lonchocarpus cyanescens Triterpenoids as Inhibitors for Malaria. Journal of Physical
Chemistry & Biophysics, 6(2).
Afriza, D., Suriyah, W. and Ichwan, S. (2018). In silicoanalysis of molecular
interactions between the anti-apoptotic protein survivin and dentatin, nordentatin, and
quercetin. Journal of Physics: Conference Series, 1073, p.032001.
Brust, J., 2012. Current Diagnosis & Treatment Neurology. 2nd ed.
Butowski, N. (2015). Epidemiology and Diagnosis of Brain Tumors. CONTINUUM:
Lifelong Learning in Neurology, 21, pp.301-313.
Daina, A., Michielin, O. and Zoete, V. (2017). SwissADME: a free web tool to
evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small
molecules. Scientific Reports, 7(1).
Dundas, J., Ouyang, Z., Tseng, J., Binkowski, A., Turpaz, Y. and Liang, J. (2006).
CASTp: computed atlas of surface topography of proteins with structural and
topographical mapping of functionally annotated residues. Nucleic Acids Research,
(Web Server), pp.W116-W118.
Forte, I., Indovina, P., Iannuzzi, C., Cirillo, D., Di Marzo, D., Barone, D., Capone,
F., Pentimalli, F. and Giordano, A. (2019). Targeted therapy based on p53 reactivation
reduces both glioblastoma cell growth and resistance to temozolomide. International
Journal of Oncology.
Guo, L., Cai, X., Lee, J., Kang, S., Shin, E., Zhou, H., Jung, J. and Kim, Y. (2008).
Comparison of suppressive effects of demethoxycurcumin and bisdemethoxycurcumin
on expressions of inflammatory mediators In Vitro and In Vivo. Archives of Pharmacal
Research, 31(4), pp.490-496.
Hari, S. (2019). In silico molecular docking and ADME/T analysis of plant
compounds against IL17A and IL18 targets in gouty arthritis. Journal of Applied
Pharmaceutical Science, 9(7), pp.18-26.
Huang, Y., Rose, P. and Hsu, C. (2015). Citing a Data Repository: A Case Study
of the Protein Data Bank. PLOS ONE, 10(8), p.e0136631.
Hucklenbroich, J., Klein, R., Neumaier, B., Graf, R., Fink, G., Schroeter, M. and
Rueger, M. (2014). Aromatic-turmerone induces neural stem cell proliferation in vitro and
in vivo. Stem Cell Research & Therapy, 5(4), p.100.
Kim, S., Thiessen, P., Bolton, E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J.,
He, S., Shoemaker, B., Wang, J., Yu, B., Zhang, J. and Bryant, S. (2015). PubChem
Substance and Compound databases. Nucleic Acids Research, 44(D1), pp.D1202-
D1213.
Klinger, N. and Mittal, S. (2016). Therapeutic Potential of Curcumin for the
Treatment of Brain Tumors. Oxidative Medicine and Cellular Longevity, 2016, pp.1-14.
Kocaadam, B. and Şanlier, N. (2015). Curcumin, an active component of turmeric
(Curcuma longa), and its effects on health. Critical Reviews in Food Science and Nutrition,
(13), pp.2889-2895.
Lipinski, C., Lombardo, F., Dominy, B. and Feeney, P. (2001). Experimental and
computational approaches to estimate solubility and permeability in drug discovery and
development settings 1PII of original article: S0169-409X(96)00423-1. The article was
originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1. Advanced
Drug Delivery Reviews, 46(1-3), pp.3-26.
Lo, J., Kamarudin, M., Hamdi, O., Awang, K. and Kadir, H. (2015). Curcumenol
isolated from Curcuma zedoaria suppresses Akt-mediated NF-κB activation and p38
MAPK signaling pathway in LPS-stimulated BV-2 microglial cells. Food & Function, 6(11),
pp.3550-3559.
Morris, G., Goodsell, D., Halliday, R., Huey, R., Hart, W., Belew, R. and Olson, A.
(1998). Automated docking using a Lamarckian genetic algorithm and an empirical
binding free energy function. Journal of Computational Chemistry, 19(14), pp.1639-1662.
Park, S., Jin, M., Kim, Y., Kim, Y. and Lee, S. (2012). Anti-inflammatory effects of
aromatic-turmerone through blocking of NF-κB, JNK, and p38 MAPK signaling pathways
in amyloid β-stimulated microglia. International Immunopharmacology, 14(1), pp.13-20.
Sulfahri, Arif, A., Iskandar, I. and Wardhani, R. (2019). In silico approach of
antidiabetic compounds from Caesalpinia crista seed through docking analysis and
ADMET predictions. Journal of Physics: Conference Series, 1341, p.022001.
Togar, B., Turkez, H., Tatar, A., Hacimuftuoglu, A. and Geyikoglu, F. (2014).
Cytotoxicity and genotoxicity of zingiberene on different neuron cell lines in
vitro. Cytotechnology, 67(6), pp.939-946.
Wang, H., Oo Khor, T., Shu, L., Su, Z., Fuentes, F., Lee, J. and Tony Kong, A.
(2012). Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability. Anti-Cancer Agents in Medicinal Chemistry,
(10), pp.1281-1305.
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang,
Y., Setiady, I., Deveau, C., Saoud, K., Grello, C., Oxford, M., Yuan, F. and Abounader, R.
(2018). The p53 Pathway in Glioblastoma. Cancers, 10(9), p.297
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Oceana Biomedicina Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
